Eletriptan

Bibliography

• Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004;24(Suppl 1):9-160
   PubMedGoogle Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45(Suppl 1):S3-13
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Zwart JA, Hagen K, Epidemiology of headache in Europe [review]. Eur J Neurol 2006;13(4):333-45
   PubMed Web of Science ®Google Scholar
• Stovner Lj, Hagen K, Jensen R, The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27(3):193-210
   PubMed Web of Science ®Google Scholar
• Lyngberg AC, Rasmussen BK, Jorgensen T, Jensen R. Incidence of primary headache: a Danish epidemiologic follow-up study. Am J Epidemiol 2005;161(11):1066-73
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. Acute pharmacotherapy of migraine, tension-type headache, and cluster headache. J Headache Pain 2007;8:127-34
   PubMedGoogle Scholar
• Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000;62(5):509-25
   PubMed Web of Science ®Google Scholar
• Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001;89(2-3):107-10
   PubMed Web of Science ®Google Scholar
• Dodick D, Liptonl RB, Martin V, The Triptan Cardiovascular Safety Expert Panel, Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004;44:414-25
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55(6):754-62
   PubMed Web of Science ®Google Scholar
• British National Formulary, edition 58; 2009. Accessed October 2009
   Google Scholar
• US Product Information for Relpax. Available from: http://media.pfizer.com/files/products/uspi_relpax.pdf. [Last accessed October 2009]
   Google Scholar
• Napier C, Stewart M, Melrose H, Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 1999;368(2-3):259-68
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000;60(6):1259-87
   PubMed Web of Science ®Google Scholar
• Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review. Clin Pharmacokinet 2001;40(3):189-205
   PubMed Web of Science ®Google Scholar
• Ottervanger JP, van Witsen TB, Valkenburg HA, Adverse reactions attributed to sumatriptan. A postmarketing study in general practice. Eur J Clin Pharmacol 1994;47:305-9
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, van den Broek RW, de Vries R, Bogers AJ, Craniovascular selectivity of eletriptan and sumatriptan in human isolated blood vessels. Neurology 2000;55(10):1524-30
   PubMed Web of Science ®Google Scholar
• Gupta P, Butler P, Shepperson NB, McHarg A. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist. Eur J Pharmacol 2000;398(1):73-81
   PubMed Web of Science ®Google Scholar
• Muir DF, McCann GP, Swan L, Hemodynamic and coronary effects of intravenous eletriptan, a 5HT1B/1D-receptor agonist. Clin Pharmacol Ther 1999;66(1):85-90
   PubMed Web of Science ®Google Scholar
• Goldstein JA, Massey KD, Kirby S, Effect of high-dose intravenous eletriptan on coronary artery diameter. Cephalalgia 2004;24(7):515-21
   PubMed Web of Science ®Google Scholar
• Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain 2008;9:5-12
   PubMed Web of Science ®Google Scholar
• Knyihar-Csillik E, Tajti J, Csillik AE, Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci 2000;12(11):3991-4002
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Hoskin KL. Differential effects of low dose CP122,288 and eletriptan on fos expression due to stimulation of the superior sagittal sinus in cat. Pain 1999;82(1):15-22
   PubMed Web of Science ®Google Scholar
• Lambert GA, Boers PM, Hoskin KL, Suppression by eletriptan of the activation of trigeminovascular sensory neurons by glyceryl trinitrate. Brain Res 2002;953(1-2):181-8
   PubMed Web of Science ®Google Scholar
• Hoskin KL, Lambert GA, Donaldson C, Zagami AS. The 5-hydroxytryptamine1B/1D/1F receptor agonists eletriptan and naratriptan inhibit trigeminovascular input to the nucleus tractus solitarius in the cat. Brain Res 2004;998(1):91-9
   PubMed Web of Science ®Google Scholar
• Milton KA, Scott NR, Allen MJ, Pharmacokinetics, pharmacodynamics, and safety of the 5-HT 1B/1D agonist eletriptan following intravenous and oral administration. J Clin Pharmacol 2002;42:528-39
   PubMed Web of Science ®Google Scholar
• Shah AK, Harris SC, Greenhalgh C, Morganroth J. The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol 2002;42:520-7
   PubMed Web of Science ®Google Scholar
• Evans DC, O'Connor D, Lake BG, Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug Metab Dispos 2003;31(7):861-9
   PubMed Web of Science ®Google Scholar
• Tepper S, Allen C, Sanders D, Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 2003;43(1):44-8. Erratum in: Headache 2003;43(7):833
   PubMed Web of Science ®Google Scholar
• Deleu D, Hanssens Y. Current and emerging second-generation triptans in acute migraine therapy: a comparative review [review]. J Clin Pharmacol 2000;40(7):687-700
   PubMed Web of Science ®Google Scholar
• Shah AK, Laboy-Goral L, Scott N, Pharmacokinetics and safety of oral eletriptan during different phases of the menstrual cycle in healthy volunteers. J Clin Pharmacol 2001;41(12):1339-44
   PubMed Web of Science ®Google Scholar
• Oldman AD, Smith LA, McQuay HJ, Moore RA. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97(3):247-57
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358(9294):1668-75
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P. A review of evidence-based medicine and meta-analytic reviews in migraine [review]. Cephalalgia 2006;26(11):1265-74
   PubMed Web of Science ®Google Scholar
• Stark R, Dahlof C, Haughie S, Hettiarachchi J; Eletriptan Steering Committee. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002;22(1):23-32
   PubMed Web of Science ®Google Scholar
• Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002;22(6):416-23
   PubMed Web of Science ®Google Scholar
• Sheftell F, Ryan R, Pitman V; Eletriptan Steering Committee. Efficacy, safety, and tolerability of oral eletriptan for treatment of acute migraine: a multicenter, double-blind, placebo-controlled study conducted in the United States. Headache 2003;43(3):202-13
   PubMed Web of Science ®Google Scholar
• Färkkilä M, Olesen J, Dahlöf C, Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:198-203
   Google Scholar
• Wells NE, Steiner TJ. Effectiveness of eletriptan in reducing time loss caused by migraine attacks. Pharmacoeconomics 2000;18(6):557-66
   PubMed Web of Science ®Google Scholar
• Salonen R, Kori S, Scott A, Richardson MS. Encapsulated sumatriptan is not bioequivalent to commercial sumatriptan. Headache 2003;43(8):923-4
   PubMed Web of Science ®Google Scholar
• Mandema JW, Cox E, Alderman J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain–results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 2005;25(9):715-25
   PubMed Web of Science ®Google Scholar
• Pascual J, Mateos V, Roig C, Marketed oral triptans in the acute treatment of migraine: a systematic review on efficacy and tolerability [review]. Headache 2007;47(8):1152-68
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Ferrari MD, Olesen J, Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000;54(1):156-63
   PubMed Web of Science ®Google Scholar
• Mathew NT, Schoenen J, Winner P, Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003;43(3):214-22, (a)
   PubMed Web of Science ®Google Scholar
• Sandrini G, Farkkila M, Burgess G, et al.; Eletriptan Steering Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology 2002;59(8):1210-17
   PubMed Web of Science ®Google Scholar
• Diener HC, Ryan R, Sun W, Hettiarachchi J. The 40-mg dose of eletriptan: comparative efficacy and tolerability versus sumatriptan 100 mg. Eur J Neurol 2005;11(2):125-34
   Web of Science ®Google Scholar
• Schoenen J, Pascual J, Rasmussen S, Patient preference for eletriptan 80 mg versus subcutaneous sumatriptan 6 mg: results of a crossover study in patients who have recently used subcutaneous sumatriptan. Eur J Neurol 2005;12(2):108-117
   PubMed Web of Science ®Google Scholar
• Vollono C, Capuano A, Mei D, Multiple attack study on the available triptans in Italy versus placebo. Eur J Neurol 2005;12(7):557-63
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Diener HC, MacGregor EA, Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 2003;23:942-52
   PubMed Web of Science ®Google Scholar
• Garcia-Ramos G, MacGregor EA, Hilliard B, Comparative efficacy of eletriptan versus naratriptan in the acute treatment of migraine. Cephalalgia 2003;23:869-76
   PubMed Web of Science ®Google Scholar
• Lainez MJ, Evers S, Kinge E, Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006;26(3):246-56
   PubMed Web of Science ®Google Scholar
• Diener HC, Jansen JP, Reches A, Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot®) in the acute treatment of migraine: a multicentre, randomized, double-blind, placebo-controlled comparison. Eur Neurol 2002;47(2):99-107
   PubMed Web of Science ®Google Scholar
• Chia Y-C, Lim S-H, Wang S-J, Efficacy of eletriptan in migraineurs with persistent poor response to nonsteroidal anti-inflammatories. Headache 2003;43:984-90
   PubMed Web of Science ®Google Scholar
• Martin VT, Loder E, Taylor K, Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: results from a multiple-attack study. Cephalalgia 2005;25(9):726-34
   PubMed Web of Science ®Google Scholar
• Diamond ML, Hettiarachchi J, Hilliard B, Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 2004;44(3):209-16
   PubMed Web of Science ®Google Scholar
• Goldstein J, Tiseo P, Denaro J, Sikes C. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006;46(7):1142-50
   PubMed Web of Science ®Google Scholar
• Pascual J. Clinical benefits of early triptan therapy for migraine. Headache 2002;42(Suppl 1):S10-17
   PubMedGoogle Scholar
• Brandes JL, Kudrow D, Cady R, Eletriptan in the early treatment of acute migraine: influence of pain intensity and time of dosing. Cephalalgia 2005;25:735-42
   PubMed Web of Science ®Google Scholar
• Mathew NT, Hettiarachchi J, Alderman J. Tolerability and safety of eletriptan in the treatment of migraine: a comprehensive review. Headache 2003;43(9):962-74, (b)
   PubMed Web of Science ®Google Scholar
• Newman CM, Starkey I, Buller N, Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries. Eur J Clin Pharmacol 2005;61(10):733-42
   PubMed Web of Science ®Google Scholar
• Hu XH, Markson LE, Lipton RB, Burden of migraine in the US: disability and economic costs. Arch Intern Med 1999;159:813-18
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, Lost productive time and cost due to common pain conditions in the US workforce. JAMA 2003;290(18):2443-54
   PubMed Web of Science ®Google Scholar
• Perfetto EM, Weis KA, Mullins CD, An economic evaluation of triptan products for migraine. Value Health 2005;8(6):647-55
   PubMed Web of Science ®Google Scholar
• Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ 1994;309:765-9
   PubMed Web of Science ®Google Scholar
• Winner P, Rothner AD, editors, Headache in children and adolescents. Hamilton, Canada, BC Decker Inc; 2001
   Google Scholar
• Powers SW, Patton SR, Hommel KA, Hershey AD. Quality of life in paediatric migraine: characterization of age-related effects using PedsQL 4.0. Cephalalgia 2004;24:120-7
   PubMed Web of Science ®Google Scholar
• Wöber-Bingöl Ç, Wöber C, Karwautz A, Clinical features of migraine: a cross-sectional study in patients aged three to sixty-nine. Cephalalgia 2004;24:12-7
   PubMed Web of Science ®Google Scholar
• Hershey AD, Winner P, Kabbouche MA, Use of the ICHD-II criteria in the diagnosis of pediatric migraine. Headache 2005;45:1288-97
   PubMed Web of Science ®Google Scholar
• Damen L, Bruijn JK, Verhagen AP, Symptomatic treatment of migraine in children: a systematic review of medication trials [review]. Pediatrics 2005;116(2):e295-302
   PubMed Web of Science ®Google Scholar
• Winner P, Linder SL, Lipton RB, Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache 2007;47(4):511-8
   PubMed Web of Science ®Google Scholar
• Zebenholzer K, Wober C, Vigl M, Wessely P. Eletriptan for the short-term prophylaxis of cluster headache. Headache 2004;44(4):361-4
   PubMed Web of Science ®Google Scholar